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Ventilatory responses to muscle metaboreflex activation in Chronic Obstructive 
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Running title: Ventilation and muscle metaboreflex in COPD.   
 
Key points summary  
- Recent evidence indicates a role for group III/IV muscle afferents in reflex control of 
the human ventilatory response to exercise.  
- Dyspnoea in chronic obstructive pulmonary disease (COPD) may be linked to this 
reflex response. 
- This study shows that activation of the muscle metaboreflex causes a ventilatory 
response in COPD patients but not in healthy controls.  
- This indicates abnormal involvement of muscle afferents in the control of ventilation 
in COPD which may be a contributing factor to exercise dyspnoea. 
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Abstract. 
Blockade of thin fibre muscle afferent feedback during dynamic exercise reduces exercise 
hyperpnoea in health and chronic obstructive pulmonary disease (COPD). Therefore, we 
hypothesised that activation of the muscle metaboreflex at rest would cause hyperpnoea. We 
evaluated the effect of muscle metaboreflex activation on ventilation, in resting COPD 
patients and healthy participants. Following a bout of rhythmic hand grip exercise, post 
exercise circulatory occlusion (PECO) was applied to the resting forearm to sustain activation 
of the muscle metaboreflex, in 18 COPD patients (FEV1/FVC ratio <70%), 9 also classified 
as chronically hypercapnic, and 9 age and gender matched controls. The cardiovascular 
response to exercise and the sustained blood pressure elevation during PECO was similar in 
patients and controls. During exercise ventilation increased by 6.64 ± 0.84 in controls and 
significantly (p < 0.05) more, 8.38 ± 0.81 l.min-1 in patients. During PECO it fell to baseline 
levels in controls but remained significantly (p < 0.05) elevated by 2.78 ± 0.51 l.min-1 in 
patients until release of circulatory occlusion, with no significant difference in responses 
between patient groups. Muscle metaboreflex activation causes increased ventilation in 
COPD patients but not in healthy participants. Chronic hypercapnia in COPD patients does 
not exaggerate this response. The muscle metaboreflex appears to be abnormally involved in 
the control of ventilation in COPD and may be a contributing factor to exercise dyspnoea. 
 
Abbreviations list. 
COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; f, respiratory 
frequency; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HCO3-, 
bicarbonate; HF, heart failure; HR, heart rate; MAP, mean arterial blood pressure; MVC, 
maximal voluntary contraction; PaCO2, partial pressure of arterial carbon dioxide; PaO2, 
partial pressure of arterial oxygen; PECO, post exercise circulatory occlusion; PETCO2, 
partial pressure of end tidal carbon dioxide; SBP, systolic blood pressure; V, minute 
ventilation. 
 
 
  
Introduction 
It is well established that cardiovascular responses to exercise are controlled in part by central 
command (Goodwin et al 1972) and partly by metabolically and mechanically sensitive thin 
fibre afferents (groups III and IV) arising from the exercising skeletal muscle (Coote et al. 
1971, McCloskey & Mitchell 1972). Selective experimental stimulation of metaboreceptive 
afferents is commonly achieved via the technique of post exercise circulatory occlusion 
(PECO). In this technique, the occlusion of blood flow immediately post exercise traps 
metabolites including; ATP, lactic acid/H+, bradykinin, arachidonic acid and its cyclo-
oxygenase products (Kaufman et al. 1983, Rotto & Kaufman, 1988, Hanna & Kaufman, 
2004) within the previously exercising muscle and so stimulates metabosensitive fibres. It has 
been consistently shown that stimulation of these afferents via PECO induces an increased 
activation of the sympathetic nervous system and a resultant pressor reflex (Alam & Smirk 
1937, Seals et al. 1988).  
Whilst the role of central command in driving exercise hyperpnoea is also well established 
(Krogh and Lindhard 1913, Eldridge et al 1981, Green et al 2007) the role of skeletal muscle 
afferent feedback in controlling the exercise hyperpnoea is more controversial. Traditionally, 
it has been considered unimportant as evidenced by the classic finding in healthy humans that 
PECO does not prevent the recovery of ventilation to resting levels (Rowell et al. 1976, Innes 
et al. 1989, Haouzi et al. 2001). However, recent evidence, involving the blockade of afferent 
feedback during dynamic exercise has revealed a contribution of muscle afferents to 
ventilatory drive (Amann et al 2010). Intrathecal administration of Fentanyl reduced exercise 
hyperpnoea in both healthy participants, chronic obstructive pulmonary disease (COPD) and 
heart failure (HF) patient groups (Gagnon et al 2012, Olson et al 2014).  Additionally, we 
have shown that in healthy participants activation of muscle afferents using PECO, combined 
with mild hypercapnia, generates a ventilatory response and there is evidence of a synergistic 
interaction between central chemoreflex activation and muscle afferent feedback (Lykidis et 
al. 2010; Bruce & White 2012, 2015).  
Patients with COPD commonly develop skeletal muscle dysfunction; both in terms of a 
decreased force generating capacity and derangements in energy metabolism. There is an 
increasing body of evidence suggesting that, alongside the respiratory impairments, skeletal 
muscle dysfunction is an important contributing factor in the exercise intolerance associated 
with the disease (see Maltais et al. 2014). A slow to fast transition of muscle fibre types 
(Whittom et al. 1998; Jobin et al. 1998; Gosker et al. 2002), increased muscle glycolytic 
enzyme activity (Jakobsson et al. 1995; Gea et al. 2001), and reduced mitochondrial density 
and (accordingly) oxidative enzyme activity (Jakobsson et al. 1995; Gosker et al. 2002, 2007) 
have been demonstrated. These maladaptations may be important determinants in reducing 
fatigue resistance commonly found in COPD.  
During exercise the increased glycolytic capacity and shift away from oxidative metabolism 
results in a greater and earlier onset muscle acidosis. (see Puente-Maestu  et al 2013, for 
review). This would be expected to generate an augmented metaboreflex, and if muscle 
afferent feedback does provide a drive to ventilation, it could contribute to dyspnoea and 
exercise intolerance. However, to our knowledge, no controlled studies have yet examined 
the ventilation of COPD patients during metaboreflex activation using PECO. Therefore the 
primary aim of this investigation is to examine the respiratory responses of patients with 
COPD to PECO, compared with age matched healthy control participants. We hypothesise 
that patients with COPD will demonstrate augmented ventilatory responses to metaboreflex 
activation.  
Secondly, based on our previous observations of a synergistic interaction between 
experimentally induced hypercapnia and metaboreflex activation, we aim to examine whether 
any respiratory response to PECO in COPD patients relates to their level of CO2 retention. 
(Lykidis et al. 2010; Bruce & White 2012, 2015). We hypothesise that chronically 
hypercapnic patients will generate a larger ventilatory response during PECO in comparison 
to normocapnic patients. 
 
Methods 
Ethical Approval 
All participants received written and verbal information regarding the experimental 
procedures prior to giving informed written consent. All subjects were habituated to all the 
experimental procedures, which conform to the declaration of Helsinki and were approved by 
an NHS ethical committee.  
 
 
Participants 
18 patients with stable moderate to severe COPD, defined according to Global Initiative for 
Obstructive Lung Disease criteria, were recruited. Patient pulmonary function data and 
participant characteristics are shown in Table 1. COPD was defined as FEV1/FVC ratio 
<70% following bronchodilator medication. Moderate COPD was defined as a FEV1% 
predicted between 50%-79% and severe COPD between 30%-49%. The medications 
prescribed to the patients are listed in Table 2. Patients were not considered stable and 
excluded from participation if in the previous 6 weeks they had been hospitalised or suffered 
an exacerbation or infection. Patients with heart failure/disease, type II diabetes, renal disease 
or an active malignancy revealed by medical history were also excluded. In total, 4 COPD 
patients had controlled hypertension managed by the prescribed antihypertensive medications 
also listed in Table 2.  All patients continued to adhere to their prescribed drug regimens 
throughout the study. 9 healthy age and gender matched controls also volunteered for this 
study. Participants visited the laboratory for one trial day following habituation. Before the 
trial day participants refrained from consuming food and caffeine in the 4 hours before the 
trial and from performing strenuous physical activity or consuming alcohol in the 12 hours 
before the trial. This study followed a within subject design with all subjects participating in 
both trials. The order of each 8 minute trial was randomised with a 30 minutes rest period in 
between.    
Experimental procedures 
Participants were seated in an upright position, held a custom made handgrip dynamometer 
with their right hand. The device was clamped to a surface top which also supported the 
participant’s right arm. Maximal voluntary contractions (MVC) were determined by 
instructing participants to perform 3-5 maximal handgrip efforts separated by one minute and 
the highest was taken as the MVC. During the experimental protocol participants maintained 
the required percentage of their MVC by matching their force output to a target force 
displayed on a computer screen positioned in front of them at eye level. The rhythmic 
isometric handgrip exercise task was performed at a duty cycle of 1 second contraction at 
50% MVC, to 1 second relaxation, and the rhythm was maintained via a metronome.  
The experimental protocol is shown in Figure 1. Prior to the start of each trial participants 
rested for 5 minutes in order to establish steady state ventilation and cardiovascular variables. 
Both trials then consisted of a 2 minute baseline recording period before a 2 minute rhythmic 
isometric handgrip exercise task. Participants then either: 
1) Rested for a further 4 minutes (Control trial) or  
2) A cuff was rapidly inflated to 200mmHg around the upper right arm by a rapid cuff 
inflator commencing 2-3 contractions before cessation of the exercise period ensuring that 
immediately after exercise circulatory occlusion was achieved and so participants went 
through a 2 minute period of PECO. Then the cuff was deflated and participants rested for 2 
minutes (PECO trial) 
The order of each 8 minute trial was randomised with a 30 minutes rest period in between.    
Respiratory and Cardiovascular measures 
Ventilation was continuously monitored with a pneumotachograph (Flowmetrics, BRDL, fr-
41 s, ultasonic pneumotachograph, CA, USA) attached to the inspiratory side of a breathing 
valve (T-Valve) with a mouthpiece. From this the respiratory frequency (f) and inspiratory 
airflows (L/sec) were measured and so minute ventilation (V) was calculated. All volumes 
recorded were converted to BTPS. The pneumotachograph was calibrated with a 3 litre 
syringe to give a linear output over the range of 0.2 L to 3 L. The partial pressure of end tidal 
CO2 (PETCO2) was recorded throughout the protocol with a rapid gas analyser (Servomex, 
1440, Sussex, UK) sampling the end tidal gases in the breathing valve. The analyser was 
calibrated using gases with a known concentration of CO2 (between 0% and 10%). Heart rate 
(HR) was derived from a 3 lead electrocardiogram (ECG; Cardiorator CR7, Cardiac Records 
Ltd, London, UK) in the lead II position. From this, heart rate (HR) was continuously 
measured. Blood pressure was measured using finger photoplethysmography (Portapress, 
Finapress Medical Systems, Amsterdam, The Netherlands) with the cuff placed on the middle 
finger, and the hand supported at heart level on an adjustable table.  
Data analysis 
Mean averages for V, f, PETCO2, HR and mean arterial pressure (MAP) during each minute of 
the trials were calculated.  The cardiovascular and ventilatory responses to exercise and 
PECO were assessed with an analysis of variance with repeated measures, and then when 
appropriate multiple comparison post hoc analysis. Comparisons between the control 
participants and COPD patients in both trials were assessed using an unpaired Student’s t-
test. Data are expressed as mean ± SEM and statistical significance was taken as (P<0.05). 
Statistical analysis was conducted using a standard statistical package (SPSS, Chicago, IL, 
USA). 
 
 
Results 
Participant characteristics 
Participant characteristics are presented in Table 1. In respect of age, resting cardiovascular 
variables and body size there were no significant differences between healthy participants and 
the patients. However, COPD patients produced a 17% lower handgrip force than healthy 
participants (P<0.05).  
Differences between trials at baseline 
The mean V, f, HR, MAP and PETCO2 during baseline are presented in Table 3. There were 
no significant differences in any of these variables between the Control and COPD 
participants.  
Respiratory responses 
Changes in mean V relative to baseline recorded during each of the 4 trials are shown in 
figures 2A and 2B. Exercise caused significant increases in V during the first and second 
minute of exercise in all trials. During the second minute of exercise, the V of healthy 
participants increased by 6.36 ± 0.79 l.min-1 and 6.64 ± 0.84 l.min-1 in the control and PECO 
trials respectively. In the COPD patients V increased by 8.1 ± 0.64 l.min-1 and 8.38 ± 0.81 
l.min-1 in control and PECO trials respectively, with higher V response in the final 30 
seconds of exercise in patients compared to the healthy participants (p <0.05). V returned to 
baseline levels in both the Healthy Control and Healthy PECO trials following exercise. V 
remained significantly above baseline during the first minute after exercise in the COPD 
Control trial (2.23 ± 0.33 l.min-1) but returned to baseline in the second minute. During the 
COPD PECO trial, V remained significantly elevated above baseline throughout PECO (3.82 
± 0.68 l.min-1 and 2.78 ± 0.51 l.min-1) only returning to baseline after cuff deflation. V during 
PECO in the COPD PECO trial was significantly higher than that in the Healthy PECO trial. 
During the recovery period, V was not significantly different from baseline in all 4 trials 
(P>0.05).  
The increased ventilation during exercise was related to change in both tidal volume and f, 
however, only the increases in f reached statistical significance, during the last minute of 
exercise, in all trials. In the COPD patients these increases were significantly (P<0.05) 
greater in comparison to the healthy participants in the control (10.6 ± 3.1 and 6.7 ± 2.2 
breaths.min-1) and PECO trials (11.6 ± 2.8 and 7.2 ± 2.9 breaths.min-1 ). Following exercise, 
during the last minute of rest in the control trials, f recovered to baseline levels in both groups 
(1.9. ± 3.3 and 0.4 ± 1.9 breaths.min-1 ).  In the PECO trials f remained significantly elevated 
above baseline levels in the COPD patients in contrast to the recovery to baseline levels seen 
in the healthy participants (4.9. ± 2.5 and 2.1 ± 2.2 breaths.min-1).   
Figure 2C and 2D shows the mean PETCO2 values during throughout the 4 trials. There was 
no significant change in PETCO2 from baseline levels within each trial and no difference 
between the trials. 
Cardiovascular responses 
Changes in mean HR and MAP relative to baseline during the 4 trials are shown in figure 2E-
H. Both MAP and HR significantly increased during exercise in the Healthy Control trial (13 
± 2.3 mmHg and 12 ± 1.5 beats.min-1; P<0.05 versus baseline), in the Healthy PECO trial (13 
± 1.6 mmHg and 14 ± 1;   P<0.05 versus baseline), in the COPD Control trial (14 ± 1.1 
mmHg and 13 ± 1 beats.min-1; P<0.05 versus baseline) and in the COPD PECO trial (13 ± 1 
mmHg and 12 ± 1.2;   P<0.05 versus baseline). MAP and HR returned to baseline levels after 
exercise in the Healthy Control and COPD Control trials. However in both the PECO trials 
MAP fell from exercise levels but remained significantly elevated above baseline during the 
2 minutes post exercise (P<0.05) and only returned to baseline after cuff deflation. There 
were no significant differences in the blood pressure responses during PECO in both the 
Healthy PECO and COPD PECO trials. During the recovery period, both MAP and HR 
values were not significantly different from baseline in all 4 trials (P>0.05).  
Hypercapnic vs. Normocapnic COPD patients 
COPD patients were separated into Hypercapnic patients (PaCO2 > 45mmHg) and 
normocapnic patients. Table 4 shows that participants in the in the hypercapnic group had a 
significantly higher resting PaCO2, arterial bicarbonate content and lower PaO2 values than 
those in the normocapnic group. No other significant differences between groups were 
observed. 
Respiratory and cardiovascular responses during the PECO trial 
Baseline V, f, PETCO2, HR and MAP in hypercapnic and normocapnic COPD patients during 
baseline of the PECO trials are shown in Table 5. As expected the PETCO2 of hypercapnic 
patients was significantly higher than normocapnic patients during baseline (+15 ± 1.3 
mmHg, P<0.05) and throughout the trial (Figure 3B). There were no significant differences 
between any other baseline variables. 
Changes in mean V relative to baseline in hypercapnic and normocapnic COPD patients 
during each minute of the PECO trial are shown in figure 3A. No significant differences in V 
were observed between the hypercapnic and normocapnic patients at any time point in the 
trial. Changes in mean HR and MAP relative to baseline in hypercapnic and normocapnic 
COPD patients during each minute of the PECO trial are shown in figure 3C and 3D. No 
significant differences in HR and MAP were observed between the hypercapnic and 
normocapnic patients at any time point in the trial. 
  
 
Discussion 
This study investigated the ventilatory and cardiovascular responses of patients with 
moderate-severe COPD and healthy aged matched controls, to rhythmic handgrip exercise 
and activation of the muscle metaboreflex. The main findings are that activation of the 
metaboreflex via PECO maintained ventilation significantly above baseline in COPD patients 
but not in the healthy controls. However, there was no difference in this response between 
hypercapnic and normocapnic COPD patients.  
During PECO, where volition and muscle force are absent, only the activity of the muscle 
metaboreflex remains increased. The magnitude of the blood pressure response generated 
during PECO is known to be a reliable indicator of the level of muscle metaboreflex 
activation (Coote et al.  1971, McCloskey & Mitchell 1972, Kaufman et al. 1983). Therefore, 
our observation of similar blood pressure elevation during PECO in the patients and healthy 
participants is good evidence of a comparable level of muscle metaboreflex activation in both 
groups.  
As expected, using PECO to maintain metaboreflex activation in isolation from central 
command and muscle mechanoreceptor activation, failed to sustain the ventilation of healthy 
participants above baseline values. This finding has been well documented in many studies of 
healthy individuals using circulatory occlusion following prior exercise e.g. handgrip and 
cycling exercise (Rowell et al. 1976, Innes et al. 1989, Haouzi et al. 2001,). This evidence 
forms a major component of the classical view that in humans, muscle afferent activation 
does not contribute to respiratory drive in exercise.  
However, in our patients we demonstrated, for the first time, a sustained elevation of 
ventilation during PECO, which suggests that activation of the muscle metaboreflex can 
generate and maintain a respiratory response following forearm exercise. This is further 
supported by the finding that ventilation only returned to baseline values post arm-cuff 
deflation and thus removal of metaboreflex activation. Our observation of a ventilatory 
response, largely driven by increased f, to activation of the muscle metaboreflex is consistent 
with other recent evidence based upon removal of afferent input during exercise. Amann et al 
(2010) showed that the hyperpnoea to dynamic cycling exercise can be attenuated by 
inhibiting the neurotransmission of group III and IV afferents from the exercising muscles via 
intrathecal administration of fentanyl. In addition, administration of this spinal anaesthesia to 
patients with COPD (Gagnon et al. 2012) and HF (Olson et al. 2014) reduced the exercise 
ventilatory response, f and sensations of dyspnoea, while enhancing cycling exercise 
endurance time. When considered together this evidence based on both removal and addition 
of muscle afferent feedback, reveals a potentially important role for it in human respiratory 
control. In addition, whereas Gagnon et al. demonstrated that muscle afferent feedback plays 
an important role in the control of the exercise hyperpnoea and may limit exercise capacity in 
COPD, our methodology has the advantage of showing that the sensitivity of the muscle 
afferent mediated control of ventilation may be increased in COPD. Furthermore, our use of 
PECO selectively activates the muscle metaboreflex and so clearly defines its contribution in 
the absence of muscle mechanoreceptor input.  
A disproportionate exercise ventilatory response in COPD is well documented and indeed our 
patients did produce a significantly greater ventilatory response during the rhythmic handgrip 
exercise task compared with healthy aged matched controls. As these patients also displayed 
an augmented ventilatory response to PECO compared with healthy controls our results 
suggest that metaboreflex activation may contribute to this characteristic excessive exercise 
ventilatory response in COPD. This contribution could be mediated by two mechanisms. 
First, a greater local metabolite accumulation in the muscle causing enhanced activation of 
the muscle metaboreflex. Second, there could be a greater central sensitivity to the same level 
of muscle afferent input.  
The first explanation is plausible as COPD is associated with the down regulation of skeletal 
muscle oxidative enzyme activity, an increased lactic acidosis and a lower muscle pH in 
exercise (Casaburi et al. 1991 Kutsuzawa et al. 1992, Gosker et al. 2002). Indeed Kutsuzawa 
et al. found an exaggerated decrease in the pH of forearm muscles during a standardized 
handgrip exercise in patients with COPD compared with healthy controls. Animal studies 
show that the arterial injection of lactic acid/H+ causes an increase in the discharge of group 
III and IV muscle afferent fibres (Rotto & Kaufman 1988) and an increase in ventilation and 
blood pressure (Rotto et al. 1989). This is likely mediated, in part, by the stimulation of acid 
sensing ion channels located on the free nerve endings of muscle afferent fibres (Li et al. 
2004; Hayes et al. 2008). Therefore the skeletal muscle dysfunction associated with COPD 
may result in a standard exercise bout producing increased stimulation of metabosensitive 
receptors, an augmented metaboreflex, and so an exaggerated ventilatory response.  
However, the blood pressure response of the COPD patients to PECO was not significantly 
different to that of healthy controls, a finding consistent with other reports using static 
handgrip exercise (Roseguini et al. 2008 and Sherman et al. 2011). This is consistent with a 
similar level of muscle afferent activation between patients and healthy controls. If so, then 
our second explanation for an augmented ventilatory response to PECO, becomes more 
appealing. Indeed, in healthy participants, we have shown that it is possible to manipulate 
acutely, the sensitivity of the respiratory control system to muscle afferent input (Lykidis et 
al. 2010; Bruce & White, 2012). These studies used exposure to mild hypercapnia to alter the 
level of central respiratory activity in combination with a controlled level of muscle afferent 
activation. Under conditions of mild hypercapnia, muscle metaboreflex activation using 
PECO generated a normal pressor response. However, the elevation of ventilation, caused by 
prior exercise was sustained, in a manner resembling the response of the COPD patients in 
the present study. This prior work suggests a differential response by central cardiovascular 
and respiratory control networks to muscle metaboreflex activation, and the present study 
supports this view.  
In additional experiments this hyperventilation, during PECO, was shown to be unrelated to 
exposure of the active muscle to hypercapnia and it was not attenuated by acute exposure to 
hyperoxia, thereby reducing peripheral chemoreflex stimulation (Bruce and White, 2015). 
These observations have been argued to be evidence of a synergistic interaction between the 
central chemoreflex and muscle afferent input (Coote 2012). This was the rationale for 
comparing hypercapnic COPD patients, normocapnic COPD patients and healthy control 
participants.  Knowing that some COPD patients retain CO2, we hypothesised that such 
patients might display an exaggerated response to PECO. However, we found no differences 
in the ventilatory responses to PECO between groups of hypercapnic and normocapnic 
COPD patients.  It appears unlikely that the level of muscle metaboreflex differed between 
the two groups as their blood pressure responses to PECO were similar. So, the explanation 
for these findings may relate to differences between chronic exposure and acute exposure to 
hypercapnia. It is known that chronic elevation of PaCO2 causes desensitisation of central 
chemoreceptors and this is classically found in CO2 retaining COPD patients (Richerson and 
Boron, 2005) but further studies are required to examine this mechanism more fully. 
Implications 
Physical inactivity is considered an important factor in the development of skeletal muscle 
dysfunction in COPD (Serres et al. 1998) playing a part in a “dyspnoea spiral” (Prefaut et al, 
1995). Patients avoid physical exertion to prevent sensations of dyspnoea, resulting in further 
deconditioning of skeletal muscles. A downward spiral may result, further exaggerating the 
exercise ventilatory response and exacerbating the sensations of dyspnoea in exercise with 
further deterioration in exercise tolerance over time. This is analogous to the “muscle 
hypothesis” used to explain effort intolerance in HF (Coats et al 1994), a patient group who 
share similar features of skeletal muscle dysfunction to COPD (Franssen et al. 2002), and 
produce augmented respiratory and cardiovascular responses to PECO (Piepoli et al. 1996, 
1999; Scott et al. 2002; Ponikowski et al. 2001; Notarius et al. 2001; Crisafulli et al. 2007; 
Olson et al. 2010).  Regardless of whether afferent feedback is increased in COPD patients, 
our results show for the first time, an exaggerated respiratory response to metaboreflex 
activation in these patients, providing new insight into the neural link between skeletal 
muscle afferent activation and exercise dyspnoea in COPD.   
Endurance training in COPD patients has been shown to improve the metabolic efficiency of 
skeletal muscle by increasing oxidative enzyme activities and reducing lactic acid production 
and skeletal muscle acidosis in exercise (Casaburi et al. 1991; Maltias et al. 1996; Whittom et 
al. 1998; Sala et al. 1999). Training of healthy subjects certainly results in attenuated muscle 
metaboreflex mediated changes in muscle sympathetic nerve activity (Sinoway et al. 1989) 
and blood pressure (Fisher and White, 1999). An improvement in skeletal muscle oxidative 
capacity and reduced muscle acidosis in exercise may therefore attenuate the stimulation of 
metabolically sensitive receptors in skeletal muscle and thus reduce the central respiratory 
drive and ventilatory response to the exercise. As such, the sensations of dyspnoea upon 
exertion may be attenuated and exercise tolerance may increase. Indeed a 6 week training 
programme of the forearm muscles in HF has shown to reduce the ventilatory and 
cardiovascular responses to PECO following rhythmic handgrip exercise (Piepoli et al. 
1996), and this was thought to be achieved through improvements in skeletal muscle 
metabolism and the reduced stimulation of the muscle metaboreflex (Piepoli et al. 2008). 
However similar studies evaluating muscle afferent adaptation to training are yet to be 
conducted in COPD patients. 
Limitations 
Although the primary objective of this study was to examine ventilatory responses to 
activation of the muscle metaboreflex, we evaluated the level of this reflex activation by 
measurement of the pressor response to PECO. Recording of muscle sympathetic nerve 
activity would provide a more direct estimation of the efferent outflow resulting from muscle 
metaboreflex activation though this still would not be a direct measure of the muscle afferent 
activity which remains impractical in human studies. The standardization of exercise 
conditions also becomes an important issue in respect of comparing responses in groups with 
different muscle strengths. In the present study the MVC’s of the patient group were on 
average 17% lower. Though they performed the same relative exercise intensity as the 
healthy controls (50% of MVC) we cannot be certain that this rhythmic isometric force x 
time integral produced the same metabolite accumulations during the crucial PECO phase of 
the experiments. If lower metabolite accumulation resulted in the patient group, due to lower 
absolute force production, then the similar pressor response to healthy participants might 
suggest an exaggerated cardiovascular response to metaboreceptor activation. However, the 
literature pertaining to sustained isometric contractions is clear that the exercise pressor 
response is unrelated to muscle strength under well controlled conditions (Fisher and White, 
2004) 
In our previous studies we had access to an in-house dynamic end tidal forcing system to 
clamp pETCO2 at a given level. Constraints of ethical approval meant that the present study 
was performed in an off site, hospital environment where we were unable to transport this 
system. As a result, in the COPD patient trials where hyperventilation during PECO was 
observed there was a slight (non-significant) fall in PETCO2. However, if anything, this would 
be expected to cause a small underestimate of the influence of muscle metaboreflex on 
ventilation in the COPD patients. Though set against this, the known desensitization of 
chemoreception in COPD patients makes its influence less likely. We also acknowledge that 
the study of ventilatory responses to muscle metaboreflex activation in the forearm muscles 
should be extended to study of the functionally more significant larger locomotor muscle 
masses of the legs. 
Conclusion 
In conclusion this study demonstrated that the activation of the metaboreflex via PECO 
increases ventilation significantly above baseline in COPD patients but not in healthy 
controls. However, these ventilatory responses to PECO were not related to PaCO2. The 
findings of this study further define the role of skeletal muscle afferent feedback in the 
augmented ventilation and sensations of dyspnoea that are associated with COPD during 
exercise. The interaction of muscle afferent feedback with other drivers of ventilation require 
further study. 
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Table legends. 
Table 1. Participant characteristics (± SD). * Significant difference from Healthy participants 
(P<0.05). FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HCO3-, 
arterial bicarbonate content. 
Table 2. Mean V, HR, MAP, and PETCO2 values recorded during the two minute baseline 
period in the Control and PECO trials for the Healthy and COPD patients. 
Table 3 Characteristics of patients (±SD) separated into hypercapnic and normocapnic 
groups. * Significant difference from Normocapnic participants (P<0.05). FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; HCO3-, arterial bicarbonate 
content. 
Table 4. Mean V, HR, MAP, and PETCO2 values recorded during the two minute baseline 
period in the PECO trials of the normocapnic and hypercapnic COPD patients. * Significant 
difference from normocapnia (P<0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Healthy COPD 
N 9 (5 male) 18 (10 male) 
Age 67.7 ± 6.1 65.1 ± 5.1 
Height (cm) 167.1 ± 4.9 162.2 ± 3.2 
Weight (Kg) 71.8 ± 3.7 75.6 ± 3.1 
Handgrip Force (N) 298 ± 45 246 ± 37* 
Resting SBP (mmHg) 125 ± 3.2 119 ± 2.4 
Resting DBP (mmHg) 78 ± 2.6 75 ± 1.9 
Resting MAP (mmHg) 93 ± 3.1 89 ± 1.6 
Resting HR (bpm) 71 ± 1.6 68 ± 1.3 
FEV1 (L) - 1.06 ± 0.3 
FEV1 (% predicted) - 42 ± 5.7 
FVC (L) - 2.35 ± 0.9 
FEV1/FVC (%) - 45 ± 3.4 
PaO2 (mmHg) - 67.4 ± 9.2  
PaCO2 (mmHg) - 43.4 ± 6.5 
pH - 7.41 ± 0.03 
HCO3- (mEq.L-1) - 27.8 ± 3.1  
Table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Trial V   (l.min-1) HR (beats.min-1) 
MAP 
(mmHg) 
PETCO2 
(mmHg) 
Healthy Control 8.72 ± 0.92 68 ± 1.3 93 ± 3.1 39 ± 1.6 
PECO 9.09 ± 1.02 69 ± 1.4 95± 3.8 39 ± 0.9 
COPD 
Control 9.94 ± 0.6 71 ± 1.6 89 ± 1.6 45 ± 2.2 
PECO 10.37 ± 0.54 72 ± 1.6 90 ± 1.9 44 ± 2.3 
Table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COPD 
normocapnic 
COPD 
hypercapnic 
N 9 (5 male) 9 (5 male) 
Age 64.3 ± 6.1 67.6 ± 5.1 
Height (cm) 160.1 ± 3.8 164.6 ± 3.2 
Weight (Kg) 76.8 ± 3.7 74.6 ± 3.1 
Handgrip Force (N) 239 ± 56 250 ± 51 
Resting SBP (mmHg) 116 ± 4.6 121 ± 3.9 
Resting DBP (mmHg) 77 ± 2.6 74 ± 1.9 
Resting MAP (mmHg) 91 ± 3.2 89 ± 3.6 
Resting HR (bpm) 71 ± 1.6 67 ± 1.3 
FEV1 (L) 1 ± 0.2 1.13 ± 0.3 
FEV1 (% predicted) 43.5 ± 5.1 40.5 ± 6.4 
FVC (L) 2.24 ± 0.7 2.45 ± 0.8 
FEV1/FVC (%) 44 ± 5.1 47 ± 4.3 
PaO2 (mmHg) 71.6 ± 5.3 63.3 ± 6.4*  
PaCO2 (mmHg) 37.7 ± 3.3 49.2 ± 2.7* 
pH 7.41 ± 0.04 7.4 ± 0.03 
HCO3 (mEq.L-1) 25.3 ± 1.4  30.2 ± 1.6* 
Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    V (l.min-1) HR (beats.min-1) MAP (mmHg) PETCO2 (mmHg) 
Normocapnia 9.9 ± 0.9 70 ± 1.6 92 ± 3.4 37 ± 1.7 
Hypercapnia 10.8 ± 0.8 74 ± 1.2 89 ± 1.6 51 ± 2.3* 
Figure legends. 
Figure 1. Schematic diagram of the 8 minute protocol for the Control and PECO trials. 
Figure 2. Change in V, MAP and HR from baseline, and PETCO2 during each minute of the 
control trial and PECO trial in COPD patients and healthy participants. The black bar 
indicates the period of circulatory occlusion. * Significant difference from Baseline value 
(P<0.05). † Significant difference between COPD patients and healthy participants. 
Figure 3. Change in V, MAP and HR from baseline, and PETCO2 during each minute of the 
PECO trials in normocapnic and hypercapnic COPD patients. The black bar indicates the 
period of circulatory occlusion. * Significant difference from Baseline value (P<0.05). † 
Significant difference between normocapnic and hypercapnic groups. 
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